6
Participants
Start Date
December 17, 2021
Primary Completion Date
July 21, 2022
Study Completion Date
August 31, 2022
Arm 1: NTLA-5001
"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
Arm 2: NTLA-5001
"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
Research Site 5, Tampa
Research Site 4, Milwaukee
Research Site 3, Houston
Research Site 2, Los Angeles
Research Site 6, Portland
Research Site 1, Boston
Research Site 10, Leeds
Research Site 8, London
Research Site 9, London
Research Site 7, Manchester
Lead Sponsor
Intellia Therapeutics
INDUSTRY